Edition:
United States

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

137.01USD
23 Apr 2018
Change (% chg)

$4.58 (+3.46%)
Prev Close
$132.43
Open
$133.00
Day's High
$137.37
Day's Low
$130.00
Volume
149,905
Avg. Vol
108,921
52-wk High
$143.37
52-wk Low
$92.77

Select another date:

Thu, Apr 19 2018

GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.

UPDATE 2-GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

* Cowen analysts expect $1.3 bln in sales by 2022 (Adds details, analyst comment, estimates, background)

BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting

* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY

BRIEF-GW Pharma Says Presenting CBD-OS Product In Advisory Committee Meeting With FDA On April 19

* GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 - SEC FILING Source text: (https://bit.ly/2HK1BW3) Further company coverage:

BRIEF-GW Pharmaceuticals Announces Receipt Of Notices Of Allowance By USPTO

* GW PHARMACEUTICALS ANNOUNCES RECEIPT OF NOTICES OF ALLOWANCE BY THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR FIVE NEW EPIDIOLEX® (CANNABIDIOL) PATENTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-GW Pharmaceuticals Receives Orphan Drug Designation From EMA For Cannabidiol For The Treatment Of Tuberous Sclerosis

* GW PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CANNABIDIOL FOR THE TREATMENT OF TUBEROUS SCLEROSIS

BRIEF-GW Pharma Says Mid Stage Study Of Seizures Drug Failed Main Goal

* GW PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS OF PHASE 2A STUDY FOR ITS PIPELINE COMPOUND GWP42006

BRIEF-GW Pharmaceuticals Announces EMA Accepts Epidiolex Marketing Authorization Application For Review

* GW PHARMACEUTICALS ANNOUNCES THE EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS EPIDIOLEX® (CANNABIDIOL) MARKETING AUTHORIZATION APPLICATION (MAA) FOR REVIEW

BRIEF-GW Pharma Announces Acceptance Of NDA Filing For Epidiolex (Cannabidiol)

* GW PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF NDA FILING FOR EPIDIOLEX® (CANNABIDIOL) IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME AND DRAVET SYNDROME Source text for Eikon: Further company coverage:

BRIEF-GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.

* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.

Select another date: